论文信息 - 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. - 字舞流文

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

M. Ezekowitz | C. January | L. Wann | W. Stevenson | C. Tracy | A. Curtis | K. Ellenbogen | J. Lowe | R. Page | W. Jackman | D. Slotwiner | N. Estes

[1] S. Yusuf,et al. Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[2] B. Gage. Can we rely on RE-LY? , 2009, The New England journal of medicine.

[3] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[4] W. Weaver,et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.